iVascular’s Luminor DCB for Femoropopliteal Disease Evaluated in LUMIFOLLOW Registry

March 18, 2026—iVascular announced 3-year follow-up results from the LUMIFOLLOW registry, a large real-world study evaluating the safety and efficacy of the Luminor paclitaxel drug-coated balloon (DCB) in the treatment of femoropopliteal artery disease. Luminor, designed for the treatment of peripheral artery disease, features the company’s TransferTech nanotechnology.

According to iVascular, LUMIFOLLOW is a multicenter, real-world registry composed of 542 patients from 15 centers in France. The company stated that the study reflects routine clinical practice and includes a broad spectrum of lesion complexity—43.6% of lesions were classified as TASC C and D; and 24.2% of treated cases were restenotic lesions.

The company reported that at 3 years, the study demonstrated 87.3% of patients remaining free from revascularization and no device-related safety concerns through follow up. The results reinforce Luminor’s long-term vessel patency and clinical durability, even in complex and high-risk femoropopliteal lesions, noted iVascular.

Professor Eric Ducasse, MD, Principal Investigator of the LUMIFOLLOW study, presented the data in February at LINC 2026, the Leipzig Interventional Course.

“In the LUMIFOLLOW study, we are able to conclude Luminor’s efficacy and safety in a real-life population,” commented Prof. Ducasse in iVascular’s press release. “The study will continue up to the 5-year follow-up, and we are confident that the efficacy will be maintained, as demonstrated in other Luminor studies.”